Clinical Trial Update: Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia [Phase 3]

View source ↗

Summary

A Phase 3 trial by Pfizer evaluated the safety and efficacy of PN-152,243 and PN-196,444 to prevent thrombocytopenia in cancer patients; the study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Thrombocytopenia

Drugs mentioned

• PN-152,243
• PN-196,444

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Thrombocytopenia | Phase 3 | Status: COMPLETED